Angelini is a medium-sized private international group. Founded in Italy in the early twentieth century, the Angelini group has offices in 25 countries. Led by President Francesco Angelini, the industrial group employs approximately 3000 people.[3]

IndustryPharma, Personal care, Machinery, Wine, Perfumery
Rome, Italy
Area served
Key people
Franco Masera (Chairman)[1]
Sergio Marullo di Condojanni (CEO)
Revenue€1.725 billion (2021)[2]
Number of employees
4491 (2021)[2]
Angelini Pharma logo

The antidepressant medication Trazodone was developed in the 1960s by scientists at Angelini.[4]

In a 2018 evaluation of firms' reputation issued by Reputation Institute, Angelini ranked 66th in general and second among life sciences companies.[5]

In 2020, Angelini took over ownership of Thermacare after Pfizer spun off the transdermal analgesic patch after its merger with GlaxoSmithKline's consumer healthcare division.

In January 2021, the Swiss biotech company Arvelle Therapeutics was acquired for $960 million.[6]


  1. ^ "Governance". Retrieved 2023-03-09.
  2. ^ a b "Annual Report 2021" (PDF). 2021.
  3. ^ Who We Are - Angelini
  4. ^ Gorecki, Dennis K.J.; Verbeeck, Roger K. (1987). "Trazondone Hydrochloride". In Forey, Klaus (ed.). Profiles of Drug Substances, Excipients and Related Methodology Vol. 16. Academic Press. p. 695. ISBN 9780080861111.
  5. ^ Redazione Aboutpharma Online. 19 April 2018. Retrieved 7 May 2018. (in Italian)
  6. ^ "Italy's Angelini to buy Swiss biotech group for $1bn". Financial Times. 2021-01-03. Retrieved 2022-07-25.

External linksEdit